# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the r...
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.